Expression of CXCR4 and breast cancer prognosis: A systematic review and meta-analysis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, Zhigang ^a   Ni, Chao ^a   Chen, Wuzhen ^a   Wu, Ping ^a   Wang, Zhen ^a   Yin, Junhua ^a   Huang, Jian ^a,b   Qiu, Fuming ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; CXCR4; Prognosis

Indexed keywords

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; LYMPHATIC METASTASIS; ODDS RATIO; RECEPTORS, CXCR4; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84893023278     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-49     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16(11):2927-2931. 10.1158/1078-0432.CCR-09-2329, 20484021.
3. John M, Busillo JLB. Regulation of CXCR4 Signaling. Biochim Biophys Acta 2007, 1768(4):952-963. 10.1016/j.bbamem.2006.11.002, 1952230, 17169327.
4. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23(7):879-894. 10.1634/stemcells.2004-0342, 15888687.
5. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107(5):1761-1767. 10.1182/blood-2005-08-3182, 16269611.
6. He H, Wang C, Shen Z, Fang Y, Wang X, Chen W, Liu F, Qin X, Sun Y. Upregulated expression of C-x-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PloS One 2013, 8(8):e71864. 10.1371/journal.pone.0071864, 3735563, 23936528.
7. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathol 2008, 215(3):211-213. 10.1002/path.2350, 18523970.
8. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006, 238(1):30-41. 10.1016/j.canlet.2005.06.021, 16046252.
9. Liberati AAD, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviewsand meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6(7):e1000100. 10.1371/journal.pmed.1000100, 2707010, 19621070.
10. Zhang M, Liu HX, Teng XD, Wang HB, Cui J, Jia SS, Gu XY, Li ZG. The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer. Ultrastruct Pathol 2012, 36(6):381-386. 10.3109/01913123.2012.728687, 23216236.
11. Parker CC, Kim RH, Li BD, Chu QD. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. J Surg Oncol 2012, 106(4):393-398. 10.1002/jso.23113, 22473623.
12. Hiller DJ, Meschonat C, Kim R, Li BD, Chu QD. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery 2011, 150(3):459-465. 10.1016/j.surg.2011.07.005, 21878231.
13. Chu QD, Holm NT, Madumere P, Johnson LW, Abreo F, Li BD. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery 2011, 149(2):193-199. 10.1016/j.surg.2010.05.016, 20598333.
14. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, Wang J, Du Q, Sun B. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 2010, 29:16. 10.1186/1756-9966-29-16, 2845107, 20181250.
15. Mizell J, Smith M, Li BD, Ampil F, Chu QD. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. Ann Surg Oncol 2009, 16(10):2711-2716. 10.1245/s10434-009-0551-0, 19593633.
16. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009, 14(12):1182-1188. 10.1634/theoncologist.2009-0161, 19939894.
17. Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Kodama R, Sanke T, Nakamura Y. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008, 8:340. 10.1186/1471-2407-8-340, 2642845, 19025611.
18. Woo SU, Bae JW, Kim CH, Lee JB, Koo BW. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 2008, 15(1):281-285. 10.1245/s10434-007-9595-1, 17763975.
19. Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 2007, 141(1):53-59. 10.1016/j.jss.2007.03.015, 17574038.
20. Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast 2006, 15(4):533-539. 10.1016/j.breast.2005.08.034, 16239110.
21. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006, 97(3):275-283. 10.1007/s10549-005-9121-8, 16344916.
22. Holm NT, Abreo F, Johnson LW, Li BD, Chu QD. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat 2009, 113(2):293-299. 10.1007/s10549-008-9921-8, 18270814.
23. Balkwill FR. The chemokine system and cancer. J Pathol 2012, 226(2):148-157. 10.1002/path.3029, 21989643.
24. Anja Müller BH, Soto H, Nianfeng GE, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
25. Debarati Mukherjee JZ. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013, 3(1):46-57. 3555200, 23359227.
26. Zhongxing Liang YY, John Votaw, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971. 3734941, 15705897.
27. Wendel C, Hemping-Bovenkerk A, Krasnyanska J, Mees ST, Kochetkova M, Stoeppeler S, Haier J. CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PloS One 2012, 7(1):e30046. 10.1371/journal.pone.0030046, 3258260, 22253872.
28. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010, 29(4):709-722. 10.1007/s10555-010-9256-x, 3175097, 20839032.
29. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 2012, 107(1):43-52. 10.1038/bjc.2012.105, 3389396, 22644306.
30. Economopoulou P, Kaklamani VG, Siziopikou K. The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist 2012, 17(11):1394-1401. 10.1634/theoncologist.2012-0163, 3500359, 22941971.
31. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013, 49(1):219-230. 10.1016/j.ejca.2012.05.005, 22683307.
32. Balkwill F. Cancer and the chemokine network. Nature reviews Cancer 2004, 4(7):540-550. 10.1038/nrc1388, 15229479.
33. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102(8):2728-2730. 10.1182/blood-2003-02-0663, 12855591.
34. Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA 2013, 110(14):E1291-1300. 10.1073/pnas.1220580110, 3619300, 23509246.